Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 5/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805044 | 0.85 | MRGPRX4 (0.64) | MAOBEGFRERBB2GAK | |
| SCHEMBL11910290 | 0.85 | MRGPRX4 (0.64) | MAOBEGFRERBB2GAK | |
| SCHEMBL22874527 | 0.84 | EGFR (0.55) | CYP1A2CYP3A4CYP2D6MAPTCYP2C9 | |
| SCHEMBL25648997 | 0.84 | EGFR (0.55) | MAOBEGFRERBB2GAK | |
| SCHEMBL2767847 | 0.83 | RAB9A (0.56) | MAPTMAOBSLC6A4 | |
| SCHEMBL29514868 | 0.82 | MAOB (0.61) | MAOBEGFRERBB2GAK | |
| SCHEMBL156718 | 0.82 | MAOB (0.61) | MAOBEGFRERBB2GAK | |
| SCHEMBL5312817 | 0.82 | EGFR (0.54) | MAOBEGFRERBB2GAK | |
| SCHEMBL29388015 | 0.82 | MAOB (0.61) | MAOBEGFRERBB2GAK | |
| SCHEMBL3700337 | 0.82 | EGFR (0.54) | MAOBEGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416232-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2023-12-28 | — | — | US | disclosed |
| EP-4237088-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Blueprint Medicines Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116710444-A | Pyrimidine compounds, compositions and pharmaceutical uses thereof | 缆图药品公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022094355-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094355-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416232-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | TYMP, DPYD, TYMS | CYP1A2 926/4885CYP3A4 469/4885CYP2D6 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.